Biogen | BIIB - Current Assets



Biogen reported $7.97B in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
AbbVie USD 27.68B 2.09B Mar/2025
Acadia Pharmaceuticals USD 960.55M 89.61M Jun/2025
ALKERMES USD 1.64B 156.24M Jun/2025
Amgen USD 26.73B 195M Jun/2025
Bayer EUR 33.75B 1.08B Jun/2025
Biogen USD 7.97B 341.7M Jun/2025
BioMarin Pharmaceutical USD 3.81B 337.43M Jun/2025
Bristol-Myers Squibb USD 33.22B 2.44B Jun/2025
Eli Lilly USD 49.85B 8.59B Jun/2025
Gilead Sciences USD 14.72B 2.18B Jun/2025
Incyte USD 3.64B 411.91M Jun/2025
Merck USD 37.07B 1.56B Jun/2025
Moderna USD 6.17B 595M Jun/2025
Neurocrine Biosciences USD 1.75B 111M Jun/2025
Novartis USD 25.94B 831M Jun/2025
Pfizer USD 43.7B 2.16B Jun/2025
PTC Therapeutics USD 2.27B 43.53M Jun/2025
Regeneron Pharmaceuticals USD 16.86B 712.2M Jun/2025
Sanofi 37.02B 7B Jun/2025
Sanofi 37.02B 5.57B Jun/2025
Sarepta Therapeutics USD 2.66B 224.45M Jun/2025
Teva Pharmaceutical Industries USD 12.62B 1.09B Jun/2025
Ultragenyx Pharmaceutical USD 719.79M 20.63M Jun/2025
United Therapeutics USD 3.83B 112.9M Jun/2025
Vertex Pharmaceuticals USD 10.43B 419.1M Jun/2025